1 HOUR CYP2C19 GENOTYPING

FDA 510(k)-Cleared and CE Marked

Rapid CYP2C19 Genotyping can aid in the implementation of genotype-guided dual antiplatelet therapy (DAPT)1
U.S. AHA/ASA guidelines2 recommend dual antiplatelet therapy (DAPT) within 12-24 hours of first stroke or TIA to prevent recurrent stroke for minor stroke or high-risk TIA. Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines recommend ticagrelor in place of clopidogrel in minor stroke/high-risk TIA patients carrying a CYP2C19 loss of function allele1. The June 2024 AHA Scientific Statement recommends CYP2C19 genetic testing for ACS and PCI patients to decrease the risk of ischemic events while reducing bleeding risks associated with ticagrelor and prasugrel treatments.3
Genomadix Cube

The Genomadix Cube System Tests for...

CYP2C19

looking for a customized solution for your organization?
Click Here

APOE

looking for a customized solution for your organization?
Click Here

Legionella

looking for a customized solution for your organization?
Click Here

Looking For A Customized Solution For Your Organization?

Click Here

Genomadix Inc. Announces Know-How License Agreement With Mayo Clinic

Genomadix Inc. Announces Know-How License Agreement with Mayo Clinic OTTAWA, ON, Aug. 29, 2022 /CNW/ – Genomadix today announced it has entered

Read More

GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM

GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM (OTTAWA, March 22, 2023) Genomadix , based in Ottawa,

Read More

Assets of Spartan Bioscience Inc. To Be Acquired By Casa-Dea Finance Limited

GENOMADIX ANNOUNCES SECURING TWO YEARS OF FUNDING Spartan Bioscience Inc. (Spartan) announces today that its primary assets will be acquired

Read More

Stanford Adds CYP2C19 Rapid Test to Genomics Menu, Plans Future PGx Expansion

Stanford Adds CYP2C19 Rapid Test to Genomics Menu, Plans Future PGx Expansion Stanford Medical Center has just introduced the Genomadix

Read More
  1. Kleindorfer DO, et al. Stroke. 2021;52:e364–e467 | 2. Pan Y, et al. JAMA Neurol. 2022;79(8):739–745
  1. Lee et al., Clin Pharmacol Ther. 2022 November ; 112(5): 959–967. doi:10.1002/cpt.2526 |
  2. Kleindorfer DO, et al. Stroke. 2021;52:e364–e467.
  3. Pereira et al. Circulation. 2024;150:e129-e150. DOI: 10.1161/CIR.0000000000001257.

Ready to start working with the
Genomadix Cube?

Contact Us
Genomadix Logo

Genomadix

340 Legget Dr,
Kanata, ON K2K 2A4

+1 888 810 7788

Technology

About

Legal

© 2024 Genomadix, the Genomadix logo and all product names are the property of Genomadix or its licensors. All rights reserved. 

X-twitter Linkedin

External social links open to a new page or tab.

Scroll to Top